>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

XOG +18.6%, PFIE +17.9%, FBIO +17.3%, HDSN +16.8%, (Hudson Technologies to acquire Airgas' (ARG) subsidiary Airgas-Refrigerants in a transaction valued on a gross basis at approximately $220 million ),RADA +15.5%, ASYS +14.6%, QUIK +11.6%, PRGO +11.5%, ATHX +10%,ATHX +10%, XXII +8.5%, ONVO +7.2%, AEG +7.1%, LYV +6.7%, CPST+6.5%, QHC +6.5%, PAAS +6.2%, HPJ +6.1%, AOSL +5.8%, ALQA +5.7%,GOOS +5.5%, EAT +5%, HRTX +4.9%, HRTX +4.9%, (reaches agreement w/ the FDA on the desing/key elements for HTX-011's Phase 3 program; co expects to file an NDA for HTX-011 in 2018), PLNT +4.8%,GERN +4.7%, CCE +4.1%, YY +4%, PRTS +4%, SCON +3.9%, NNA +3.7%,CYCC +3.6%, BXE +3.6%, SENS +3.4%, RARX +3%, FOXA +2.9%, AMFW+2.6%, RESN +2.2%, CPA +2.2%, ALNY +2.1%, PIRS +2%, DIN +1.9%,EDIT +1.8%, (Editas Medicine achieves a second milestone under its collaboration with Juno Therapeutics (JUNO); co will receive $2.5 million for achieving this milestone), SLF +1.6%, (to commence a normal course issuer bid of up to 11.5 mln common shares), JACK+1.4%, SSRM +1.1%, CSRA +1%, EGLT +0.9%

M&A news:

SKLN +19.3% (Skyline Medical signs definitive merger agreement with CytoBioscience in transaction expected to close by September 30, 2017), .

Other news:

GLPG +17.5% (Galapagos NV announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA Phase 2a trial )
ANTH +15.1% (receives orphan drug designation from the FDA for the treatment of Immunoglobulin A nephropathy)
AGTC +2% (filed an IND with the FDA to conduct a Phase 1/2 clinical trial of the company's gene therapy product candidate)
ACRX +1.5% (after closing near highs), .

Analyst comments: